KOE:290650
L&C Bio Co., Ltd · KOE · Healthcare · KRW · FY for 2025
Figures on this page computed 2026-11-07 22:17 UTC
Last close
n/aKRW
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
1.1%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-161.7%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-3.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.47Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.1%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
What it pays out is the furthest below its sector's middle: 0.04 against 0.36 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.95x
Its own average over 10 years, 43.78B.
- Profit-14.01x
Its own average over 10 years, 9.86B.
- Free cash flow0.37x
Its own average over 10 years, -8.81B.
- Debt2.27x
Its own average over 10 years, 40.62B.
- Pricen/a
Its own average over 0 years. Market data
Profit is furthest from its own average, at -14.01 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 151.4 | 189.4 | 104.3 |
| 2018-12-31 | 179.7 | 262.9 | 250.6 |
| 2019-12-31 | 246.6 | 366.0 | 286.5 |
| 2020-12-31 | 278.9 | 545.8 | 285.5 |
| 2021-12-31 | 386.4 | 697.3 | 290.8 |
| 2022-12-31 | 444.7 | 229.4 | 295.8 |
| 2023-12-31 | 582.6 | 2,441.1 | 322.4 |
| 2024-12-31 | 609.8 | 7,120.3 | 328.5 |
| 2025-12-31 | 723.0 | -6,974.5 | 642.0 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
Figures behind the shape
Growth
21.0%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate21.0%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
One-year change in net income-197.9%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
Returns on capital
1.1%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capital1.1%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity-69.7%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets-30.3%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
48.4%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin48.4%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin4.0%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin-161.7%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin-3.8%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
5.9xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
Price to book5.9x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA106.4x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio13.7x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.47safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equity0.47
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio0.59
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage0.6x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score3.08
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
0.1%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yield0.1%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio-2.9x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.